MyDx, Inc. announced earnings results for the year 2017. For the year, the company's adjusted EBITDA increased 69% year over year due to rising gross margins, becoming more efficient with its marketing spend and scaling back non-critical R&D expenses. Gross Profit Margins rose to 73%, which favors MyDx’s long-term strategy, and gross profits remained relatively flat at $306,000, despite CannaDx revenues falling 37%, year over year. The positive effect on margins, in part, is due to successfully re-negotiating supplier contracts for the manufacture of its CannaDx product line and the discontinuing the use of certain distributors to sell its products, which also played a part in the decrease of revenues. Total revenues were also impacted by a recalibration of its marketing spend, and halting the direct licensing of its data, which will instead be bundled into the MyDx360TM service.